Search | IOVS | ARVO Journals

Access Provided By:
MIT Libraries

Forgot password?

Create an Account

View

Showing 1 – 4 of 4

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract June 2021

Twelve-month Findings from Two Phase 1/2 Clinical Studies of Subretinal Gene Therapy Drugs for Achromatopsia

Mark E Pennesi; Paul Yang; Andreas Lauer; Robert A Sisk; Jason M Comander; Rachel M. Huckfeldt; Edward Averbuhk; Eyal Banin; Ninel Gregori; Janet L Davis; Byron L Lam; Christine Kay; Erin Leone; Deanine Halliman; Nnenna Ihekoromadu; Matthew Feinsod

Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):3321.

ARVO Annual Meeting Abstract June 2021

Six Month Findings from a Phase 1/2 Clinical Study of Subretinal Gene Therapy Drug AGTC-501 for X-Linked Retinitis Pigmentosa Show Clinically Meaningful Improvement in Macular Sensitivity

Paul Yang; Andreas Lauer; Mark E Pennesi; David G Birch; rand spencer; Robert A Sisk; Alessandro Iannaccone; Erin Leone; Deanine Halliman; Nnenna Ihekoromadu; Matthew Feinsod

Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):1481.

ARVO Annual Meeting Abstract June 2015

Safety and Efficacy of DE-117, a Selective EP 2 Agonist in a Phase 2a Study

Nnenna Ihekoromadu; Fenghe Lu; Ryo Iwamura; Kenji Yoneda; Noriko Kawabata-Odani; Naveed Kamal Shams

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):5708.

ARVO Annual Meeting Abstract June 2013

Comparison of Pharmacokinetic profiles of Sirolimus following Subconjunctival or Intravitreal Administrations in Rabbits and Humans

Masaaki Kageyama; Joel Naor; Hitomi Takanaga; Laura Wilson; Nnenna Ihekoromadu; Afsheen Khwaja; Sri Mudumba

Invest. Ophthalmol. Vis. Sci.. 2013; 54(15):5370.

Advertisement